Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strattera (correction)

Executive Summary

Lilly's attention deficit/hyperactivity disorder medication Strattera has been used in 3.4 mil. patients worldwide, the company says. "The Pink Sheet" (1Oct. 2, 2005, p. 8) incorrectly reported the figure as 2 mil. based on an FDA press release. Additionally, labeling for Shire's Adderall XR was inaccurately reported in the story. The amphetamine therapy carries a "black box" warning advising of drug dependence. A similar boxed warning is included under the Warnings section of Johnson & Johnson's Concerta...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS046420

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel